HPLC Monitoring of Malondialdehyde in Patients with Endometrial and Ovarial Cancer
AbstraktA method for determination of malondialdehyde (MDA) as the major biomarker of oxidative damage of cellular membranes was developed. MDA was transformed to its 2,4-dinitrophenylhydrazone, which was then separated by HPLC. The LOD and repeatability of the method is satisfactory for monitoring MDA in blood plasma. The performed clinical study revealed systematically enhanced MDA levels in patients with gynaecological carcinoma in comparison with the control group.